Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis.

Harrold LR, Shan Y, Connolly SE, Alemao E, Rebello S, Guo L, Kremer JM.

Curr Med Res Opin. 2019 Oct 15:1. doi: 10.1080/03007995.2019.1680354. [Epub ahead of print]

PMID:
31612736
2.

Machine learning to predict anti-TNF drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers.

Guan Y, Zhang H, Quang D, Wang Z, Parker SCJ, Pappas DA, Kremer JM, Zhu F.

Arthritis Rheumatol. 2019 Jul 24. doi: 10.1002/art.41056. [Epub ahead of print]

PMID:
31342661
3.

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.

Pappas DA, Etzel CJ, Zlotnick S, Best J, Blachley T, Kremer JM.

Rheumatol Ther. 2019 Sep;6(3):421-433. doi: 10.1007/s40744-019-0162-6. Epub 2019 Jun 25.

4.

Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.

Cohen SB, Kremer JM, Dandreo KJ, Reed GW, Magner R, Shan Y, Kafka S, DeHoratius RJ, Ellis L, Parenti D.

Clin Rheumatol. 2019 Sep;38(9):2501-2508. doi: 10.1007/s10067-019-04543-z. Epub 2019 May 2.

PMID:
31049762
5.

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

Dervieux T, Kremer JM, Weinblatt ME.

Ann Rheum Dis. 2019 Sep;78(9):1285-1286. doi: 10.1136/annrheumdis-2018-214860. Epub 2019 Mar 18. No abstract available.

6.

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry.

Harrold LR, Litman HJ, Connolly SE, Alemao E, Kelly S, Rebello S, Hua W, Kremer JM.

Rheumatol Ther. 2019 Jun;6(2):217-230. doi: 10.1007/s40744-019-0149-3. Epub 2019 Mar 13.

7.

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.

PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019.

8.

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ.

J Rheumatol. 2019 May;46(5):475-482. doi: 10.3899/jrheum.171034. Epub 2019 Jan 15.

PMID:
30647182
9.

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.

Harrold LR, Reed GW, Best J, Zlotnick S, Kremer JM.

Rheumatol Ther. 2018 Dec;5(2):507-523. doi: 10.1007/s40744-018-0127-1. Epub 2018 Oct 6.

10.

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P.

Rheumatology (Oxford). 2018 Nov 1;57(11):2001-2011. doi: 10.1093/rheumatology/key182.

11.

Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.

Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR.

J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1.

12.

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry.

Pappas DA, Gerber RA, Litman HJ, Gruben D, Geier J, Hua WD, Chen C, Li Y, Kremer JM, Andrews JS, Bourret JA.

Am Health Drug Benefits. 2018 May;11(3):148-158.

13.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

PMID:
29908669
14.

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.

Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffith J.

Clin Rheumatol. 2018 Aug;37(8):2275-2280. doi: 10.1007/s10067-018-4140-0. Epub 2018 Jun 4.

15.

Elevated atmospheric carbon dioxide concentrations promote ant tending of aphids.

Kremer JMM, Nooten SS, Cook JM, Ryalls JMW, Barton CVM, Johnson SN.

J Anim Ecol. 2018 Sep;87(5):1475-1483. doi: 10.1111/1365-2656.12842. Epub 2018 May 17.

PMID:
29700820
16.

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.

Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD.

Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25.

PMID:
29696436
17.

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.

Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M.

Arthritis Rheumatol. 2018 Aug;70(8):1200-1208. doi: 10.1002/art.40493. Epub 2018 Jun 14.

18.

Transcriptome landscape of a bacterial pathogen under plant immunity.

Nobori T, Velásquez AC, Wu J, Kvitko BH, Kremer JM, Wang Y, He SY, Tsuda K.

Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E3055-E3064. doi: 10.1073/pnas.1800529115. Epub 2018 Mar 12. Erratum in: Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):E11564.

19.

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.

Kremer JM, Schiff M, Muram D, Zhong J, Alam J, Genovese MC.

RMD Open. 2018 Jan 13;4(1):e000581. doi: 10.1136/rmdopen-2017-000581. eCollection 2018.

20.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. Review.

21.

Draft genome of the fungicidal biological control agent Burkholderia anthina strain XXVI.

de Los Santos-Villalobos S, Kremer JM, Parra-Cota FI, Hayano-Kanashiro AC, García-Ortega LF, Gunturu SK, Tiedje JM, He SY, Peña-Cabriales JJ.

Arch Microbiol. 2018 Jul;200(5):803-810. doi: 10.1007/s00203-018-1490-6. Epub 2018 Feb 10.

PMID:
29428982
22.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS.

Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.

23.

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.

Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M.

Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31.

24.

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M.

Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5.

25.

Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

J Rheumatol. 2018 Jan;45(1):32-39. doi: 10.3899/jrheum.170007. Epub 2017 Nov 1.

26.

Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject.

Ocon A, Peredo-Wende R, Kremer JM, Bhatt BD.

Lupus. 2018 Feb;27(2):347-348. doi: 10.1177/0961203317734921. Epub 2017 Oct 9. No abstract available.

PMID:
28992799
27.

Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.

Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL.

Semin Arthritis Rheum. 2018 Feb;47(4):472-477. doi: 10.1016/j.semarthrit.2017.07.010. Epub 2017 Aug 2.

PMID:
28947312
28.

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR.

Arthritis Rheumatol. 2018 Jan;70(1):49-59. doi: 10.1002/art.40323.

29.

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.

Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, Best J, Zlotnick S, Kremer JM, Greenberg JD.

Rheumatol Ther. 2017 Dec;4(2):405-417. doi: 10.1007/s40744-017-0081-3. Epub 2017 Sep 21.

30.

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.

Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V.

Rheumatol Ther. 2017 Dec;4(2):375-389. doi: 10.1007/s40744-017-0077-z. Epub 2017 Aug 24.

31.

Superior Displacement of the Dens in a Patient With Rheumatoid Arthritis.

Martinez-Singh K, Bhatt BD, Peredo-Wende R, Kremer JM.

J Clin Rheumatol. 2018 Mar;24(2):95-96. doi: 10.1097/RHU.0000000000000567. No abstract available.

PMID:
28816768
32.

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM.

Clin Rheumatol. 2017 Sep;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2. Epub 2017 Jul 17.

33.

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.

Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A, Dimonaco S, Brockwell L.

Arthritis Rheumatol. 2017 Sep;69(9):1751-1761. doi: 10.1002/art.40176. Epub 2017 Aug 1.

34.

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

Kremer JM, Weinblatt ME.

Ann Rheum Dis. 2018 Jan;77(1):e4. doi: 10.1136/annrheumdis-2017-211632. Epub 2017 Jun 8. No abstract available.

PMID:
28596184
35.

Fish Oil and Inflammation - A Fresh Look.

Kremer JM.

J Rheumatol. 2017 Jun;44(6):713-716. doi: 10.3899/jrheum.161551. No abstract available.

PMID:
28572471
36.

Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.

Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6.

37.

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.

Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S.

Arthritis Res Ther. 2017 Apr 27;19(1):81. doi: 10.1186/s13075-017-1289-x.

38.

Design characteristics of the Corrona Japan rheumatoid arthritis registry.

Yamanaka H, Kishimoto M, Pappas DA, Greenberg JD, Kremer JM, Tanaka Y.

Mod Rheumatol. 2018 Jan;28(1):95-100. doi: 10.1080/14397595.2017.1317383. Epub 2017 Apr 27.

PMID:
28448195
39.

Sex differences in gout characteristics: tailoring care for women and men.

Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD.

BMC Musculoskelet Disord. 2017 Mar 14;18(1):108. doi: 10.1186/s12891-017-1465-9.

40.

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

Clin Rheumatol. 2017 Jun;36(6):1215-1220. doi: 10.1007/s10067-017-3588-7. Epub 2017 Mar 1.

41.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL.

Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.

42.

The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.

Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H.

Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):310-319. doi: 10.1002/pds.4126. Epub 2016 Dec 28.

43.

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.

Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM.

Arthritis Res Ther. 2016 Dec 1;18(1):280.

44.

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez Bursón JM, Genovese MC, Combe B.

Ann Rheum Dis. 2017 Apr;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821. Epub 2016 Oct 31.

45.

Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.

Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S.

Arthritis Rheumatol. 2017 Apr;69(4):735-741. doi: 10.1002/art.39966.

46.

The Corrona US registry of rheumatic and autoimmune diseases.

Kremer JM.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S96-S99. Epub 2016 Oct 19. Review.

47.

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry.

Pappas DA, Kent JD, Greenberg JD, Mason MA, Kremer JM, Holt RJ.

Rheumatol Ther. 2015 Dec;2(2):153-164. Epub 2015 Sep 29.

48.

Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.

Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD.

Rheumatol Ther. 2016 Jun;3(1):103-115. doi: 10.1007/s40744-016-0028-0. Epub 2016 Feb 8.

49.

Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.

Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV.

Arthritis Care Res (Hoboken). 2017 Apr;69(4):592-598. doi: 10.1002/acr.23004.

50.

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.

Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC.

Arthritis Rheumatol. 2016 Dec;68(12):2867-2877. doi: 10.1002/art.39801.

Supplemental Content

Loading ...
Support Center